Immuron (IMRN) has submitted an Investigational New Drug application to the FDA for clinical development of IMM-529. The company is proposing the development of IMM-529 for treatment of Clostridioides difficile infection and prevention of recurrent CDI.
The company plans to initiate a Phase 2 trial for IMM-529 in individuals with Clostridioides difficile infection during the first half of 2026. IMM-529 specifically targets Toxin B, the spores, and the surface layer proteins of the vegetative cells.
Shares of Immuron are up 8% in pre-market trade on Wednesday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.